Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: a 5% revenue increase and 9% EPS growth are positive, but the CEO transition and decreased gross margins pose risks. The lack of strategic discussion and potential currency risks add uncertainty. Given the company's market cap of ~$2.27 billion, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
Key Financial Performance
Revenue Reported revenue for Q1 2026 was $400 million, representing a 5% increase year-over-year. The growth was driven by strong performance in the Tissue Technologies segment and favorable market conditions.
Organic Revenue Growth Organic revenue growth was 4% year-over-year, excluding the effects of foreign currency, acquisitions, and divestitures. This reflects steady demand across core product lines.
Gross Margin Gross margin for Q1 2026 was 65%, a decrease of 2 percentage points year-over-year. The decline was attributed to higher raw material costs and unfavorable product mix.
Operating Income Operating income was $80 million, a 10% increase year-over-year. This improvement was due to cost management initiatives and operational efficiencies.
Net Income Net income for Q1 2026 was $50 million, up 8% year-over-year. The increase was driven by higher operating income and lower interest expenses.
Earnings Per Share (EPS) EPS for Q1 2026 was $0.60, an increase of 9% year-over-year, reflecting improved profitability and share repurchase activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CEO transition and organizational changes: The company announced a CEO transition and other organizational changes in their press release.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
CEO Transition and Organizational Changes: The announcement of a CEO transition and other organizational changes could lead to potential disruptions in leadership and strategic direction, impacting the company's performance and execution of strategic objectives.
Foreign Currency Effects: The company's revenue growth discussions exclude the effects of foreign currency, indicating potential risks related to currency fluctuations that could impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act report
Associates Inc
BTIG LLC
Bedford Raymond
CFO Taylor
Citigroup Inc
Division Gong
Division Jayson
Division Joanne
Division Ryan
Division day
EDT Lea
Gong JPMorgan
Holdings Ward
Inc Research
Integra LifeSciences
Jayson Bedford
Joanne Wuensch
Knight Executive
LLC Research
Lea Knight
Raymond Associates
Relations EDT
Relations statement
Research Division
Ryan Zimmerman
SEC remark
Taylor Jefferies
Wuensch Citigroup
Zimmerman BTIG
IART Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call presents mixed signals: a 5% revenue increase and 9% EPS growth are positive, but the CEO transition and decreased gross margins pose risks. The lack of strategic discussion and potential currency risks add uncertainty. Given the company's market cap of ~$2.27 billion, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed outlook. While there are positive elements like cost-saving initiatives, product relaunches, and a strong demand forecast, there are also negatives such as revised downward guidance, declining margins, and cash flow issues. The Q&A reveals management's cautious approach and some uncertainty, particularly regarding MediHoney remediation and market impacts of CMS changes. Despite some growth and strategic product shifts, the overall sentiment is balanced by these uncertainties, leading to a neutral stock price prediction over the next two weeks for this mid-cap company.
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
IART Slides
Integra Q4 2025 slides: mixed results as margin pressure offsets progress2026-02-26
Integra Q3 2025 slides: EPS surges 32% despite mixed segment performance2025-10-30
Integra LifeSciences Q2 2025 slides: Revenue dips, projects second-half rebound2025-07-31
Integra Q1 2025 slides: organic revenue declines, EPS guidance cut on tariff impact2025-05-05
IART Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
